LGT Group Foundation grew its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 14.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 82,702 shares of the company's stock after purchasing an additional 10,355 shares during the period. LGT Group Foundation's holdings in Zoetis were worth $13,475,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Darwin Wealth Management LLC acquired a new stake in Zoetis during the third quarter worth approximately $31,000. First Personal Financial Services acquired a new stake in shares of Zoetis during the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new position in shares of Zoetis in the third quarter worth $33,000. Dunhill Financial LLC raised its stake in Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC lifted its position in Zoetis by 482.8% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 140 shares during the period. 92.80% of the stock is owned by institutional investors.
Zoetis Price Performance
Shares of ZTS traded up $0.26 during midday trading on Thursday, reaching $167.26. The stock had a trading volume of 3,010,514 shares, compared to its average volume of 3,273,812. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $74.90 billion, a price-to-earnings ratio of 30.58, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company's 50-day moving average is $166.57 and its 200 day moving average is $176.99. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33.
Zoetis (NYSE:ZTS - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. On average, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.
Zoetis Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.20%. Zoetis's dividend payout ratio (DPR) is presently 36.56%.
Wall Street Analysts Forecast Growth
Several equities analysts have commented on ZTS shares. Leerink Partners initiated coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price on the stock. Piper Sandler lifted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. StockNews.com cut Zoetis from a "buy" rating to a "hold" rating in a research note on Tuesday, February 25th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $215.90.
Check Out Our Latest Research Report on ZTS
Insider Buying and Selling at Zoetis
In other news, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the sale, the executive vice president now directly owns 16,107 shares of the company's stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.16% of the company's stock.
About Zoetis
(
Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
